Prof. Dr. Michael Weller
Targeting the mutation in gliomas by CRISPR/Cas precision base editing.
Weber R, Vasella F, Klimko A, Silginer M, Lamfers M, Neidert M, Regli L, Schwank G, Weller M. Targeting the mutation in gliomas by CRISPR/Cas precision base editing. Neurooncol Adv 2024; 6:vdae182.
02.11.2024Targeting the mutation in gliomas by CRISPR/Cas precision base editing.
02.11.2024Neurooncol Adv 2024; 6:vdae182
Weber Remi, Vasella Flavio, Klimko Artsiom, Silginer Manuela, Lamfers Martine, Neidert Marian Christoph, Regli Luca, Schwank Gerald, Weller Michael
High-throughput identification of repurposable neuroactive drugs with potent anti-glioblastoma activity.
Lee S, Weiss T, Bühler M, Mena J, Lottenbach Z, Wegmann R, Sun M, Bihl M, Augustynek B, Baumann S, Goetze S, van Drogen A, Pedrioli P, Penton D, Festl Y, Buck A, Kirschenbaum D, Zeitlberger A, Neidert M, Vasella F, Rushing E, Wollscheid B, Hediger M, Weller M, Snijder B. High-throughput identification of repurposable neuroactive drugs with potent anti-glioblastoma activity. Nat Med 2024; 30:3196-3208.
20.09.2024High-throughput identification of repurposable neuroactive drugs with potent anti-glioblastoma activity.
20.09.2024Nat Med 2024; 30:3196-3208
Lee Sohyon, Weiss Tobias, Bühler Marcel, Mena Julien, Lottenbach Zuzanna, Wegmann Rebekka, Sun Miaomiao, Bihl Michel P, Augustynek Bartłomiej, Baumann Sven P, Goetze Sandra, van Drogen Audrey, Pedrioli Patrick G A, Penton David, Festl Yasmin, Buck Alicia, Kirschenbaum Daniel, Zeitlberger Anna, Neidert Marian Christoph, Vasella Flavio, Rushing Elisabeth Jane, Wollscheid Bernd, Hediger Matthias A, Weller Michael, Snijder Berend
Role of microsurgical tumor burden reduction in patients with breast cancer brain metastases considering molecular subtypes: a two-center volumetric survival analysis.
Bellomo J, Zeitlberger A, Padevit L, Stumpo V, Gönel M, Fierstra J, Nierobisch N, Reimann R, Witzel I, Weller M, Le Rhun E, Bozinov O, Regli L, Neidert M, Serra C, Voglis S. Role of microsurgical tumor burden reduction in patients with breast cancer brain metastases considering molecular subtypes: a two-center volumetric survival analysis. J Neurooncol 2024; 169:379-390.
03.06.2024Role of microsurgical tumor burden reduction in patients with breast cancer brain metastases considering molecular subtypes: a two-center volumetric survival analysis.
03.06.2024J Neurooncol 2024; 169:379-390
Bellomo Jacopo, Zeitlberger Anna Maria, Padevit Luis, Stumpo Vittorio, Gönel Meltem, Fierstra Jorn, Nierobisch Nathalie, Reimann Regina, Witzel Isabell, Weller Michael, Le Rhun Emilie, Bozinov Oliver, Regli Luca, Neidert Marian Christoph, Serra Carlo, Voglis Stefanos
Integrative spatial analysis reveals a multi-layered organization of glioblastoma.
Greenwald A, Darnell N, Hoefflin R, Simkin D, Mount C, Gonzalez Castro L, Harnik Y, Dumont S, Hirsch D, Nomura M, Talpir T, Kedmi M, Goliand I, Medici G, Laffy J, Li B, Mangena V, Keren-Shaul H, Weller M, Addadi Y, Neidert M, Suvà M, Tirosh I. Integrative spatial analysis reveals a multi-layered organization of glioblastoma. Cell 2024; 187:2485-2501.e26.
22.04.2024Integrative spatial analysis reveals a multi-layered organization of glioblastoma.
22.04.2024Cell 2024; 187:2485-2501.e26
Greenwald AliC, Darnell Noam Galili, Hoefflin Rouven, Simkin Dor, Mount Christopher W, Gonzalez Castro L Nicolas, Harnik Yotam, Dumont Sydney, Hirsch Dana, Nomura Masashi, Talpir Tom, Kedmi Merav, Goliand Inna, Medici Gioele, Laffy Julie, Li Baoguo, Mangena Vamsi, Keren-Shaul Hadas, Weller Michael, Addadi Yoseph, Neidert Marian Christoph, Suvà Mario L, Tirosh Itay
A phase Ib/II randomized, open-label drug repurposing trial of glutamate signaling inhibitors in combination with chemoradiotherapy in patients with newly diagnosed glioblastoma: the GLUGLIO trial protocol.
Mastall M, Roth P, Bink A, Maranta A, Läubli H, Hottinger A, Hundsberger T, Migliorini D, Ochsenbein A, Seystahl K, Imbach L, Hortobágyi T, Held L, Weller M, Wirsching H. A phase Ib/II randomized, open-label drug repurposing trial of glutamate signaling inhibitors in combination with chemoradiotherapy in patients with newly diagnosed glioblastoma: the GLUGLIO trial protocol. BMC cancer 2024; 24:82.
15.01.2024A phase Ib/II randomized, open-label drug repurposing trial of glutamate signaling inhibitors in combination with chemoradiotherapy in patients with newly diagnosed glioblastoma: the GLUGLIO trial protocol.
15.01.2024BMC cancer 2024; 24:82
Mastall Maximilian, Roth Patrick, Bink Andrea, Maranta Angela Fischer, Läubli Heinz, Hottinger Andreas Felix, Hundsberger Thomas, Migliorini Denis, Ochsenbein Adrian F, Seystahl Katharina, Imbach Lukas L, Hortobágyi Tibor, Held Leonhard, Weller Michael, Wirsching Hans-Georg
A prognostic model for tumor recurrence and progression after meningioma surgery: preselection for further molecular work-up.
Padevit L, Vasella F, Friedman J, Mutschler V, Jenkins F, Held U, Rushing E, Wirsching H, Weller M, Regli L, Neidert M. A prognostic model for tumor recurrence and progression after meningioma surgery: preselection for further molecular work-up. Front Oncol 2023; 13:1279933.
01.11.2023A prognostic model for tumor recurrence and progression after meningioma surgery: preselection for further molecular work-up.
01.11.2023Front Oncol 2023; 13:1279933
Padevit Luis, Vasella Flavio, Friedman Jason, Mutschler Valentino, Jenkins Freya Sophie, Held Ulrike, Rushing Elisabeth Jane, Wirsching Hans-Georg, Weller Michael, Regli Luca, Neidert Marian Christoph
Glioblastoma in the oldest old: Clinical characteristics, therapy, and outcome in patients aged 80 years and older.
Stadler C, Gramatzki D, Le Rhun E, Hottinger A, Hundsberger T, Roelcke U, Läubli H, Hofer S, Seystahl K, Wirsching H, Weller M, Roth P. Glioblastoma in the oldest old: Clinical characteristics, therapy, and outcome in patients aged 80 years and older. Neurooncol Pract 2023; 11:132-141.
20.10.2023Glioblastoma in the oldest old: Clinical characteristics, therapy, and outcome in patients aged 80 years and older.
20.10.2023Neurooncol Pract 2023; 11:132-141
Stadler Christina, Gramatzki Dorothee, Le Rhun Emilie, Hottinger Andreas Felix, Hundsberger Thomas, Roelcke Ulrich, Läubli Heinz, Hofer Silvia, Seystahl Katharina, Wirsching Hans-Georg, Weller Michael, Roth Patrick
MGMT methylation pattern of long-term and short-term survivors of glioblastoma reveals CpGs of the enhancer region to be of high prognostic value.
Leske H, Camenisch Gross U, Hofer S, Neidert M, Leske S, Weller M, Lehnick D, Rushing E. MGMT methylation pattern of long-term and short-term survivors of glioblastoma reveals CpGs of the enhancer region to be of high prognostic value. Acta Neuropathol Commun 2023; 11:139.
28.08.2023MGMT methylation pattern of long-term and short-term survivors of glioblastoma reveals CpGs of the enhancer region to be of high prognostic value.
28.08.2023Acta Neuropathol Commun 2023; 11:139
Leske Henning, Camenisch Gross Ulrike, Hofer Silvia, Neidert Marian Christoph, Leske Sabine, Weller Michael, Lehnick Dirk, Rushing Elisabeth Jane
A T-cell antigen atlas for meningioma: novel options for immunotherapy.
Medici G, Freudenmann L, Velz J, Wang S, Kapolou K, Paramasivam N, Mühlenbruch L, Kowalewski D, Vasella F, Bilich T, Frey B, Dubbelaar M, Patterson A, Zeitlberger A, Silginer M, Roth P, Weiss T, Wirsching H, Krayenbühl N, Bozinov O, Regli L, Rammensee H, Rushing E, Sahm F, Walz J, Weller M, Neidert M. A T-cell antigen atlas for meningioma: novel options for immunotherapy. Acta Neuropathol 2023; 146:173-190.
27.06.2023A T-cell antigen atlas for meningioma: novel options for immunotherapy.
27.06.2023Acta Neuropathol 2023; 146:173-190
Medici Gioele, Freudenmann Lena Katharina, Velz Julia, Wang Sophie Shih-Yüng, Kapolou Konstantina, Paramasivam Nagarajan, Mühlenbruch Lena, Kowalewski Daniel Johannes, Vasella Flavio, Bilich Tatjana, Frey Beat M, Dubbelaar MariLisa, Patterson Angelica Brooke, Zeitlberger Anna Maria, Silginer Manuela, Roth Patrick, Weiss Tobias, Wirsching Hans-Georg, Krayenbühl Niklaus, Bozinov Oliver, Regli Luca, Rammensee Hans-Georg, Rushing Elisabeth Jane, Sahm Felix, Walz Juliane Sarah, Weller Michael, Neidert Marian Christoph
Microbial peptides activate tumour-infiltrating lymphocytes in glioblastoma.
Naghavian R, Faigle W, Oldrati P, Wang J, Toussaint N, Qiu Y, Medici G, Wacker M, Freudenmann L, Bonté P, Weller M, Regli L, Amigorena S, Rammensee H, Walz J, Brugger S, Mohme M, Zhao Y, Sospedra M, Neidert M, Martin R. Microbial peptides activate tumour-infiltrating lymphocytes in glioblastoma. Nature 2023; 617:807-817.
17.05.2023Microbial peptides activate tumour-infiltrating lymphocytes in glioblastoma.
17.05.2023Nature 2023; 617:807-817
Naghavian Reza, Faigle Wolfgang, Oldrati Pietro, Wang Jianwen, Toussaint Nora C, Qiu Yuhan, Medici Gioele, Wacker Marcel, Freudenmann Lena Katharina, Bonté Pierre-Emmanuel, Weller Michael, Regli Luca, Amigorena Sebastian, Rammensee Hans-Georg, Walz Juliane Sarah, Brugger Silvio D, Mohme Malte, Zhao Yingdong, Sospedra Mireia, Neidert Marian Christoph, Martin Roland
Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4+ T-cell Responses in Glioblastoma.
Wang J, Weiss T, Neidert M, Toussaint N, Naghavian R, Sellés Moreno C, Foege M, Tomas Ojer P, Medici G, Jelcic I, Schulz D, Rushing E, Dettwiler S, Schrörs B, Shin J, McKay R, Wu C, Lutterotti A, Sospedra M, Moch H, Greiner E, Bodenmiller B, Regli L, Weller M, Roth P, Martin R. Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4+ T-cell Responses in Glioblastoma. Clin Cancer Res 2022; 28:5368-5382.
15.12.2022Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4+ T-cell Responses in Glioblastoma.
15.12.2022Clin Cancer Res 2022; 28:5368-5382
Wang Jian, Weiss Tobias, Neidert Marian C, Toussaint Nora C, Naghavian Reza, Sellés Moreno Carla, Foege Magdalena, Tomas Ojer Paula, Medici Gioele, Jelcic Ivan, Schulz Daniel, Rushing Elisabeth, Dettwiler Susanne, Schrörs Barbara, Shin Joo Heon, McKay Ron, Wu Catherine J, Lutterotti Andreas, Sospedra Mireia, Moch Holger, Greiner Erich F, Bodenmiller Bernd, Regli Luca, Weller Michael, Roth Patrick, Martin Roland
Association of perioperative adverse events with subsequent therapy and overall survival in patients with WHO grade III and IV gliomas.
Weber L, Padevit L, Müller T, Velz J, Vasella F, Voglis S, Gramatzki D, Weller M, Regli L, Sarnthein J, Neidert M. Association of perioperative adverse events with subsequent therapy and overall survival in patients with WHO grade III and IV gliomas. Front Oncol 2022; 12:959072.
28.09.2022Association of perioperative adverse events with subsequent therapy and overall survival in patients with WHO grade III and IV gliomas.
28.09.2022Front Oncol 2022; 12:959072
Weber Lorenz, Padevit Luis, Müller Timothy, Velz Julia, Vasella Flavio, Voglis Stefanos, Gramatzki Dorothee, Weller Michael, Regli Luca, Sarnthein Johannes, Neidert Marian Christoph
Maximal surgical tumour load reduction in immune-checkpoint inhibitor naïve patients with melanoma brain metastases correlates with prolonged survival.
Voglis S, Schaller V, Müller T, Gönel M, Winklhofer S, Mangana J, Dummer R, Serra C, Weller M, Regli L, Le Rhun E, Neidert M. Maximal surgical tumour load reduction in immune-checkpoint inhibitor naïve patients with melanoma brain metastases correlates with prolonged survival. Eur J Cancer 2022; 175:158-168.
17.09.2022Maximal surgical tumour load reduction in immune-checkpoint inhibitor naïve patients with melanoma brain metastases correlates with prolonged survival.
17.09.2022Eur J Cancer 2022; 175:158-168
Voglis Stefanos, Schaller Valentina, Müller Timothy, Gönel Meltem, Winklhofer Sebastian, Mangana Joana, Dummer Reinhard, Serra Carlo, Weller Michael, Regli Luca, Le Rhun Emilie, Neidert Marian C
Anatomical phenotyping and staging of brain tumours.
Akeret K, Vasella F, Staartjes V, Velz J, Müller T, Neidert M, Weller M, Regli L, Serra C, Krayenbühl N. Anatomical phenotyping and staging of brain tumours. Brain 2022; 145:1162-1176.
29.04.2022Anatomical phenotyping and staging of brain tumours.
29.04.2022Brain 2022; 145:1162-1176
Akeret Kevin, Vasella Flavio, Staartjes Victor E, Velz Julia, Müller Timothy, Neidert Marian Christoph, Weller Michael, Regli Luca, Serra Carlo, Krayenbühl Niklaus
Integrated Molecular-Morphologic Meningioma Classification: A Multicenter Retrospective Analysis, Retrospectively and Prospectively Validated
German Consortium on Aggressive Meningiomas (KAM), Ratliff M, Neidert M, Wirsching H, Harter P, Unterberg A, Herold-Mende C, Jungwirth G, Etminan N, Lamszus K, Westphal M, Hänggi D, Jungk C, Mawrin C, Platten M, Snuderl M, Sahm F, von Deimling A, Preusser M, Weller M, Wick W, Acker T, Reifenberger G, Jones D, Pfister S, Frank S, Hench J, Brandner S, Aldape K, Sen C, Golfinos J, Serrano J, Stein M, Dohmen H, Reuss D, Dogan H, Patel A, Blume C, Euskirchen P, Sill M, Schrimpf D, Berghoff A, Sievers P, Hielscher T, Stichel D, Reinhardt A, Suwala A, Grady C, Jones T, Bridges L, Greenway F, Leu S, Jaunmuktane Z, Schittenhelm J, Ketter R, Bewerunge-Hudler M, Rushing E, Ricklefs F, Baumgarten P, Wefers A, Maas S. Integrated Molecular-Morphologic Meningioma Classification: A Multicenter Retrospective Analysis, Retrospectively and Prospectively Validated. J Clin Oncol 2021; 39:3839-3852.
07.10.2021Integrated Molecular-Morphologic Meningioma Classification: A Multicenter Retrospective Analysis, Retrospectively and Prospectively Validated
07.10.2021J Clin Oncol 2021; 39:3839-3852
German Consortium on Aggressive Meningiomas (KAM), Ratliff Miriam, Neidert Marian Christoph, Wirsching Hans-Georg, Harter Patrick N, Unterberg Andreas, Herold-Mende Christel, Jungwirth Gerhard, Etminan Nima, Lamszus Katrin, Westphal Manfred, Hänggi Daniel, Jungk Christine, Mawrin Christian, Platten Michael, Snuderl Matija, Sahm Felix, von Deimling Andreas, Preusser Matthias, Weller Michael, Wick Wolfgang, Acker Till, Reifenberger Guido, Jones David T W, Pfister Stefan M, Frank Stephan, Hench Jürgen, Brandner Sebastian, Aldape Kenneth D, Sen Chandra, Golfinos John, Serrano Jonathan, Stein Marco, Dohmen Hildegard, Reuss David, Dogan Helin, Patel Areeba, Blume Christina, Euskirchen Philipp, Sill Martin, Schrimpf Daniel, Berghoff Anna S, Sievers Philipp, Hielscher Thomas, Stichel Damian, Reinhardt Annekathrin, Suwala Abigail K, Grady Conor, Jones Timothy, Bridges Leslie R, Greenway Fay E A, Leu Severina, Jaunmuktane Zane, Schittenhelm Jens, Ketter Ralf, Bewerunge-Hudler Melanie, Rushing Elisabeth J, Ricklefs Franz, Baumgarten Peter, Wefers Annika K, Maas Sybren L N
Fitness-to-drive for glioblastoma patients: Guidance from the Swiss Neuro-Oncology Society (SwissNOS) and the Swiss Society for Legal Medicine (SGRM)
Hofer S, Baumert B, Läubli H, Gramatzki D, Reinert M, Pesce G, Schucht P, Frank I, Lehnick D, Weiss T, Wirsching H, Wolpert F, Roth P, Eggenberger N, Pflugshaupt T, Keller K, Imbach L, Roelcke U, Hutter G, Hundsberger T, Hertler C, Le Rhun E, Vasella F, Cordier D, Neidert M, Hottinger A, Migliorini D, Weller M. Fitness-to-drive for glioblastoma patients: Guidance from the Swiss Neuro-Oncology Society (SwissNOS) and the Swiss Society for Legal Medicine (SGRM). Swiss Med Wkly 2021; 151:w20501.
16.05.2021Fitness-to-drive for glioblastoma patients: Guidance from the Swiss Neuro-Oncology Society (SwissNOS) and the Swiss Society for Legal Medicine (SGRM)
16.05.2021Swiss Med Wkly 2021; 151:w20501
Hofer Silvia, Baumert Brigitta, Läubli Heinz, Gramatzki Dorothee, Reinert Michael, Pesce Gianfranco, Schucht Philippe, Frank Irène, Lehnick Dirk, Weiss Tobias, Wirsching Hans-Georg, Wolpert Fabian, Roth Patrick, Eggenberger Noemi, Pflugshaupt Tobias, Keller Kristina, Imbach Lukas, Roelcke Ulrich, Hutter Gregor, Hundsberger Thomas, Hertler Caroline, Le Rhun Emilie, Vasella Flavio, Cordier Dominik, Neidert Marian Christoph, Hottinger Andreas, Migliorini Denis, Weller Michael
HLA Ligand Atlas: a benign reference of HLA-presented peptides to improve T-cell-based cancer immunotherapy
Marcu A, Walz J, Velz J, Moch H, Regli L, Silginer M, Weller M, Löffler M, Erhard F, Schlosser A, Kohlbacher O, Stevanovic S, Rammensee H, Kapolou K, Martin R, Hauri-Hohl M, Bichmann L, Kuchenbecker L, Kowalewski D, Freudenmann L, Backert L, Mühlenbruch L, Szolek A, Lübke M, Wagner P, Engler T, Matovina S, Wang J, Neidert M. HLA Ligand Atlas: a benign reference of HLA-presented peptides to improve T-cell-based cancer immunotherapy. J Immunother Cancer 2021; 9
01.01.2021HLA Ligand Atlas: a benign reference of HLA-presented peptides to improve T-cell-based cancer immunotherapy
01.01.2021J Immunother Cancer 2021; 9
Marcu Ana, Walz Juliane Sarah, Velz Julia, Moch Holger, Regli Luca, Silginer Manuela, Weller Michael, Löffler Markus W, Erhard Florian, Schlosser Andreas, Kohlbacher Oliver, Stevanovic Stefan, Rammensee Hans-Georg, Kapolou Konstantina, Martin Roland, Hauri-Hohl Mathias, Bichmann Leon, Kuchenbecker Leon, Kowalewski Daniel Johannes, Freudenmann Lena Katharina, Backert Linus, Mühlenbruch Lena, Szolek András, Lübke Maren, Wagner Philipp, Engler Tobias, Matovina Sabine, Wang Jian, Neidert Marian Christoph
MRI and FET-PET Predict Survival Benefit from Bevacizumab Plus Radiotherapy in Patients with Isocitrate Dehydrogenase Wild-type Glioblastoma: Results from the Randomized ARTE Trial
Wirsching H, Tabatabai G, Ochsenbein A, Roth P, Remonda L, Conen K, Caparrotti F, von Moos R, Hottinger A, Hundsberger T, Weller J, Roelcke U, Weller M. MRI and FET-PET Predict Survival Benefit from Bevacizumab Plus Radiotherapy in Patients with Isocitrate Dehydrogenase Wild-type Glioblastoma: Results from the Randomized ARTE Trial. Clin Cancer Res 2020; 27:179-188.
23.09.2020MRI and FET-PET Predict Survival Benefit from Bevacizumab Plus Radiotherapy in Patients with Isocitrate Dehydrogenase Wild-type Glioblastoma: Results from the Randomized ARTE Trial
23.09.2020Clin Cancer Res 2020; 27:179-188
Wirsching Hans-Georg, Tabatabai Ghazaleh, Ochsenbein Adrian, Roth Patrick, Remonda Luca, Conen Katrin, Caparrotti Francesca, von Moos Roger, Hottinger Andreas F, Hundsberger Thomas, Weller Jonathan, Roelcke Ulrich, Weller Michael
Sensitivity of human meningioma cells to the cyclin-dependent kinase inhibitor, TG02
von Achenbach C, von Deimling A, Schneider H, Lawhon T, Rushing E, Neidert M, Sievers P, Wang S, Sahm F, Le Rhun E, Weller M. Sensitivity of human meningioma cells to the cyclin-dependent kinase inhibitor, TG02. Transl Oncol 2020; 13:100852.
08.09.2020Sensitivity of human meningioma cells to the cyclin-dependent kinase inhibitor, TG02
08.09.2020Transl Oncol 2020; 13:100852
von Achenbach Caroline, von Deimling Andreas, Schneider Hannah, Lawhon Tracy, Rushing Elisabeth J, Neidert Marian Christoph, Sievers Philipp, Wang Sophie S, Sahm Felix, Le Rhun Emilie, Weller Michael
CDKN2A/B homozygous deletion is associated with early recurrence in meningiomas
Sievers P, Etminan N, Ratliff M, Herold-Mende C, Pfister S, Jones D, Weller M, Harter P, Wick W, Preusser M, von Deimling A, Westphal M, Lamszus K, Reifenberger G, Hielscher T, Schrimpf D, Stichel D, Reuss D, Berghoff A, Neidert M, Wirsching H, Mawrin C, Ketter R, Paulus W, Sahm F. CDKN2A/B homozygous deletion is associated with early recurrence in meningiomas. Acta Neuropathol 2020; 140:409-413.
08.07.2020CDKN2A/B homozygous deletion is associated with early recurrence in meningiomas
08.07.2020Acta Neuropathol 2020; 140:409-413
Sievers Philipp, Etminan Nima, Ratliff Miriam, Herold-Mende Christel, Pfister Stefan M, Jones David T W, Weller Michael, Harter Patrick N, Wick Wolfgang, Preusser Matthias, von Deimling Andreas, Westphal Manfred, Lamszus Katrin, Reifenberger Guido, Hielscher Thomas, Schrimpf Daniel, Stichel Damian, Reuss David E, Berghoff Anna S, Neidert Marian Christoph, Wirsching Hans-Georg, Mawrin Christian, Ketter Ralf, Paulus Werner, Sahm Felix